Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Health Catalyst

Nasdaq:HCAT
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HCAT
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations primarily in the United States. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Health Catalyst has significant price volatility in the past 3 months.
HCAT Share Price and Events
7 Day Returns
13.4%
NasdaqGS:HCAT
2.4%
US Healthcare Services
-4.1%
US Market
1 Year Returns
-
NasdaqGS:HCAT
16.3%
US Healthcare Services
-14.9%
US Market
HCAT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Health Catalyst (HCAT) 13.4% -9.8% -21% - - -
US Healthcare Services 2.4% -4.3% -2.4% 16.3% 61.9% 36.3%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • No trading data on HCAT.
  • No trading data on HCAT.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

HCAT Value

 Is Health Catalyst undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Health Catalyst to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Health Catalyst.

NasdaqGS:HCAT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:HCAT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.98
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.975 (1 + (1- 21%) (5.2%))
1.01
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.01
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.01 * 5.44%)
7.23%

Discounted Cash Flow Calculation for NasdaqGS:HCAT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Health Catalyst is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGS:HCAT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.23%)
2020 -25.28 Analyst x3 -23.57
2021 -17.19 Analyst x3 -14.95
2022 25.50 Analyst x1 20.68
2023 57.50 Analyst x1 43.48
2024 86.00 Analyst x1 60.65
2025 108.40 Est @ 26.05% 71.29
2026 128.73 Est @ 18.76% 78.95
2027 146.31 Est @ 13.65% 83.67
2028 161.05 Est @ 10.08% 85.89
2029 173.25 Est @ 7.58% 86.16
Present value of next 10 years cash flows $492.00
NasdaqGS:HCAT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $173.25 × (1 + 1.74%) ÷ (7.23% – 1.74%)
$3,207.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,207.79 ÷ (1 + 7.23%)10
$1,595.30
NasdaqGS:HCAT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $492.00 + $1,595.30
$2,087.30
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,087.30 / 37.26
$56.03
NasdaqGS:HCAT Discount to Share Price
Calculation Result
Value per share (USD) From above. $56.03
Current discount Discount to share price of $27.19
= -1 x ($27.19 - $56.03) / $56.03
51.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Health Catalyst is available for.
Intrinsic value
>50%
Share price is $27.19 vs Future cash flow value of $56.03
Current Discount Checks
For Health Catalyst to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Health Catalyst's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Health Catalyst's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Health Catalyst's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Health Catalyst's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:HCAT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-12.86
NasdaqGS:HCAT Share Price ** NasdaqGS (2020-04-02) in USD $27.19
United States of America Healthcare Services Industry PE Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 39.64x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Health Catalyst.

NasdaqGS:HCAT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:HCAT Share Price ÷ EPS (both in USD)

= 27.19 ÷ -12.86

-2.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Health Catalyst is loss making, we can't compare its value to the US Healthcare Services industry average.
  • Health Catalyst is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Health Catalyst's expected growth come at a high price?
Raw Data
NasdaqGS:HCAT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
69%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 3.11x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Health Catalyst, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Health Catalyst's assets?
Raw Data
NasdaqGS:HCAT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.47
NasdaqGS:HCAT Share Price * NasdaqGS (2020-04-02) in USD $27.19
United States of America Healthcare Services Industry PB Ratio Median Figure of 38 Publicly-Listed Healthcare Services Companies 3.36x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGS:HCAT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:HCAT Share Price ÷ Book Value per Share (both in USD)

= 27.19 ÷ 5.47

4.97x

* Primary Listing of Health Catalyst.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Health Catalyst is overvalued based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess Health Catalyst's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Health Catalyst has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HCAT Future Performance

 How is Health Catalyst expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Health Catalyst expected to grow at an attractive rate?
  • Unable to compare Health Catalyst's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Health Catalyst's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Health Catalyst's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:HCAT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:HCAT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 69%
NasdaqGS:HCAT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 16.4%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 23.8%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:HCAT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:HCAT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 389 1
2023-12-31 329 1
2022-12-31 272 -38 5
2021-12-31 227 -13 -50 9
2020-12-31 187 -27 -55 9
2020-04-03
NasdaqGS:HCAT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 155 -32 -241
2019-09-30 148 -32 -304
2019-06-30 141 -33 -282
2019-03-31 127 -38 -190
2018-12-31 113 -40 -114
2017-12-31 73 -37 -59

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Health Catalyst is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Health Catalyst's revenue is expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:HCAT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Health Catalyst Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:HCAT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 -1.11 -1.11 -1.11 1.00
2021-12-31 -1.25 -0.95 -1.52 3.00
2020-12-31 -1.41 -1.22 -1.53 3.00
2020-04-03
NasdaqGS:HCAT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -12.86
2019-09-30 -28.31
2019-06-30 -58.75
2019-03-31 -39.75
2018-12-31 -23.76
2017-12-31 -12.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Health Catalyst will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Health Catalyst's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Health Catalyst has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HCAT Past Performance

  How has Health Catalyst performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Health Catalyst's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Health Catalyst does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Health Catalyst's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Health Catalyst's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Health Catalyst's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Health Catalyst Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:HCAT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 154.94 -240.92 78.69 46.22
2019-09-30 147.52 -304.31 76.17 43.71
2019-06-30 140.97 -282.12 68.86 40.62
2019-03-31 127.16 -190.03 71.27 39.36
2018-12-31 112.57 -114.02 65.55 38.08
2017-12-31 73.08 -58.78 40.62 28.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Health Catalyst has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Health Catalyst has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Health Catalyst improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Health Catalyst's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Health Catalyst has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HCAT Health

 How is Health Catalyst's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Health Catalyst's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Health Catalyst is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Health Catalyst's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Health Catalyst's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Health Catalyst Company Filings, last reported 3 months ago.

NasdaqGS:HCAT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 200.64 48.20 228.28
2019-09-30 206.55 47.92 241.42
2019-06-30 27.43 47.64 54.08
2019-03-31 35.90 47.26 64.63
2018-12-31 35.08 20.10 33.19
2017-12-31 62.09 9.62 51.46
  • Health Catalyst's level of debt (24%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Health Catalyst's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Health Catalyst has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Health Catalyst has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Health Catalyst's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Health Catalyst has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HCAT Dividends

 What is Health Catalyst's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Health Catalyst dividends.
If you bought $2,000 of Health Catalyst shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Health Catalyst's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Health Catalyst's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:HCAT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 29 Stocks 0.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:HCAT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Health Catalyst has not reported any payouts.
  • Unable to verify if Health Catalyst's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Health Catalyst's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Health Catalyst has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Health Catalyst's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Health Catalyst afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Health Catalyst has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HCAT Management

 What is the CEO of Health Catalyst's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dan Burton
COMPENSATION $4,572,740
AGE 44
TENURE AS CEO 7.5 years
CEO Bio

Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has many years of strategy and leadership experience. He co-founded HB Ventures and has filled senior executive roles at HB Ventures portfolio companies, including the roles of Chief Executive Officer, President and Chief Marketing Officer. Prior to HB Ventures, Mr. Burton led the Corporate Strategy Group at Micron Technology. He served as President of Health Catalyst, Inc. from September 2011 to October 2012. He also spent eight years with Hewlett-Packard in Strategy and Management roles, including building and managing a technology e-business. Before joining HP, he served as an Associate Consultant with the Boston Consulting Group, where he advised healthcare systems and technology companies. Mr. Burton holds an MBA with High Distinction from Harvard University, where he was elected a George F. Baker Scholar and a BS in economics, magna cum laude, from BYU.

CEO Compensation
  • Insufficient data for Dan to compare compensation growth.
  • Dan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Health Catalyst management team in years:

3.4
Average Tenure
53.5
Average Age
  • The tenure for the Health Catalyst management team is about average.
Management Team

Dan Burton

TITLE
CEO & Director
COMPENSATION
$5M
AGE
44
TENURE
7.5 yrs

J. Patrick Nelli

TITLE
Chief Financial Officer
COMPENSATION
$2M
TENURE
2.6 yrs

Dale Sanders

TITLE
Chief Technology Officer
COMPENSATION
$3M
AGE
59
TENURE
1.2 yrs

Steve Barlow

TITLE
Co-Founder & Senior VP (Leave of Absence)
TENURE
12.3 yrs

Tom Burton

TITLE
Co-Founder & President of Professional Services
TENURE
12.3 yrs

Paul Horstmeier

TITLE
Chief Operating Officer
AGE
58
TENURE
1.5 yrs

Adam Brown

TITLE
Senior Vice President of Investor Relations

Dan Orenstein

TITLE
General Counsel & Secretary
AGE
49
TENURE
4.3 yrs

Trudy Sullivan

TITLE
Chief Communications & Diversity & Inclusion Officer
TENURE
0.9 yrs

Kyle Salyers

TITLE
Senior Vice President of Corporate Development
Board of Directors Tenure

Average tenure and age of the Health Catalyst board of directors in years:

5.6
Average Tenure
59
Average Age
  • The tenure for the Health Catalyst board of directors is about average.
Board of Directors

Dan Burton

TITLE
CEO & Director
COMPENSATION
$5M
AGE
44
TENURE
8.6 yrs

Todd Cozzens

TITLE
Independent Director
COMPENSATION
$40K
AGE
63
TENURE
7.6 yrs

D. Bullock

TITLE
Independent Director
AGE
66
TENURE
5.9 yrs

Jack Kane

TITLE
Independent Director
COMPENSATION
$50K
AGE
66
TENURE
5.3 yrs

Mike Dixon

TITLE
Independent Director
AGE
34
TENURE
8.6 yrs

Promod Haque

TITLE
Independent Director
AGE
71
TENURE
7.3 yrs

Anita Pramoda

TITLE
Independent Director
COMPENSATION
$35K
AGE
44
TENURE
4 yrs

Duncan Gallagher

TITLE
Independent Director
COMPENSATION
$120K
AGE
59
TENURE
2.9 yrs

Timothy Ferris

TITLE
Director
COMPENSATION
$390K
AGE
56
TENURE
2.3 yrs

Julie Larson-Green

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Health Catalyst's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Health Catalyst has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HCAT News

Simply Wall St News

HCAT Company Info

Description

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services. The company offers Data Operating System (DOS), a data platform that allows customers to integrate and organize their disparate data sources to enable analytics, including healthcare-specific terminology, data governance, and meta-data management. It also develops foundational software applications comprising Population Builder application that enables clinicians and administrators to author, manage, view, and publish pre-built and custom population ruleset definitions; Touchstone application for benchmarking solutions; and Leading Wisely application for dashboards and reporting solutions. In addition, the company provides domain-specific software applications, such as CORUS application for activity-based costing; patient safety monitor analytics; care management services; population health foundations solutions; and quality and regulatory measures solutions. Further, it offers analytics accelerators, which facilitate analytic insights across clinical, financial, and operational use-cases. Additionally, the company provides data and analytics services, including data engineering, analytic engineer, implementation, data science, analytics strategy, and data governance services; and clinical, financial, and operational services comprising quality and process improvement strategy, patient safety, cost accounting, population health and value-based care, abstraction data submission, and health catalyst university educational services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.

Details
Name: Health Catalyst, Inc.
HCAT
Exchange: NasdaqGS
Founded: 2008
$1,013,004,343
37,256,504
Website: http://www.healthcatalyst.com
Address: Health Catalyst, Inc.
3165 Millrock Drive,
Suite 400,
Salt Lake City,
Utah, 84121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS HCAT Common Stock Nasdaq Global Select US USD 25. Jul 2019
Number of employees
Current staff
Staff numbers
900
Health Catalyst employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 03:49
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.